Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Salarius Pharmaceuticals (NASDAQ:SLRX) was downgraded by analysts at
Wal
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.